Crohn’s disease and ulcerative colitis are both inflammatory bowel diseases with similar symptoms. However, some key differences include the areas they affect, diagnostic tools, and treatment plans.

Inflammatory bowel disease (IBD) is expected to be more accurate and personalized. Recently, Professor Lee Hong-seop's team ...

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes ulcers to form in the lining of your colon and rectum. Research shows a link between UC and colorectal cancer.

Crohn’s is one of two conditions classified as inflammatory bowel disease (IBD). The other type is ulcerative colitis (UC). Generally, IBD is associated with digestive symptoms. However ...

That includes J&J’s anti-IL-23p19 antibody Tremfya (guselkumab) – in late-stage development for UC and Crohn’s – and AbbVie’s IL-23 inhibitor Skyrizi (risankizumab), which is already ...

The two main types of IBD are ulcerative colitis and Crohn’s disease. The sections below will discuss these in more detail. This condition causes inflammation in the large intestine or colon.

Crohn’s disease is one of two main types of inflammatory bowel disease (IBD). The other is ulcerative colitis. With Crohn’s, your digestive tract becomes swollen and irritated. The most common ...

Ulcerative colitis (UC) is one of the two major types of chronic inflammatory bowel diseases (IBD), along with Crohn’s disease. UC affects the large bowel, has no known cure, and requires lifelong ...

The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction ...

Tremfya is also approved to treat patients with plaque psoriasis, active psoriatic arthritis and ulcerative colitis and is ...

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...